The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
about
MHC class I characterization of Indonesian cynomolgus macaquesMemory CD8+ T cells are required for protection from persistent hepatitis C virus infectionDNA vaccines against human immunodeficiency virus type 1.A statistical framework for modeling HLA-dependent T cell response data.A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine.CD8+ T cells as a source of IFN-γ production in human cutaneous leishmaniasis.Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimenB-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection.Human immunodeficiency virus type 1 (HIV-1)-specific CD8+-T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes.What Has 30 Years of HIV Vaccine Research Taught Us?Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44(+)CD62L(high) IL-7R(+) CTLs with up- and downregulation of anti- and pro-apoptosis genes.Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.Mucosal AIDS vaccines: current status and future directions.MVA as a vector for vaccines against HIV-1.Progress on new vaccine strategies against chronic viral infectionsPooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials.Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses.Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.Two sides of a cellular coin: CD4(+)CD3- cells regulate memory responses and lymph-node organization.Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response.T cell cross-reactivity and conformational changes during TCR engagement.Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity.Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infectionKinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infectionPredicting the impact of a nonsterilizing vaccine against human immunodeficiency virus.Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys.Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa.Clonal focusing of epitope-specific CD8+ T lymphocytes in rhesus monkeys following vaccination and simian-human immunodeficiency virus challenge.HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting.Modelling the impact of antigen kinetics on T-cell activation and response
P2860
Q24655548-EB5309A9-D684-42ED-8908-C9EFD2C82310Q27485119-B6F036BC-43B5-466C-B0B9-DA5B944D0168Q30342130-7E030F0F-A80A-44D4-B03B-0C0ECE11DEE4Q31133137-11B24B66-5A76-4D30-87E9-CB3E875EF806Q31143293-A105F663-2583-4671-BDEA-8CA7F7DE518DQ33576984-6ACBFB49-F74A-4AC6-A29F-C499AED5B798Q33725704-1FC72809-D262-46F4-9BB1-A6F17438AD5AQ34142869-5661919C-DDE2-4B6E-AA98-CB06BD1E3338Q34239109-4149B1F1-5B2D-431C-8539-9519D085C73AQ34351301-57E91FC4-2376-454E-B936-A4004C186599Q35826634-C9CBB2F0-DB0E-4537-AB5E-E7E13CD80059Q35833636-492CB794-3610-4B2A-98CD-393A6EB75DCAQ35849596-DA2B4A17-01E5-462E-BAD8-2B2F6CCD1655Q35851782-E3D5DE94-67DE-488D-9C4C-EABDB8C40F6DQ35851793-7A6A1B14-B7F5-4A2D-AB8B-F0E6B3DA505BQ35864857-5CC2DAF7-ED56-48AA-B220-7796AF2742C9Q35919760-C663EA25-772D-4394-A9B6-9DB2E617954BQ36017811-E8A8DAE5-FD19-462C-B47E-4833EB6AB70BQ36050577-AA1B8987-9FEB-4903-A748-ADDB8A5DB67EQ36202186-83F6BB4D-771C-481A-8D46-7EFCF0635710Q36399559-40FA5E21-3A2F-47CC-85FD-2DDB005636C7Q36399643-B59EEB1D-D753-4917-83FE-224E93C00629Q36473515-DC3958F0-7265-44F7-8BA2-2261E667DB72Q37262408-F1987B83-6828-4523-81E4-EB826F2E87F4Q37484850-FEAF5F59-1E7F-4549-8AD8-5305250FCCB3Q37492847-AB74D6EF-5910-4246-8DAD-9AA286BC6F53Q37568241-5680B5D9-4AEF-4B41-84A7-6614041F8D6CQ38206519-31325488-92F2-4653-B134-1783A8D5B81EQ39996538-99E2D712-33C3-4D04-B6C1-6F1E70330DB0Q40551477-27253B82-814D-40FE-B8A3-D73F82303F59Q41914685-A4747F9B-9896-452C-A5C3-0CC4E3AD585CQ45601776-6A47184B-1FB7-4B8C-B451-7A74556B4502Q57213464-D7AAFB25-44EF-4FA9-9BAD-2BFB3011DEE6
P2860
The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
@ast
The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
@en
The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
@nl
type
label
The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
@ast
The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
@en
The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
@nl
prefLabel
The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
@ast
The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
@en
The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
@nl
P2860
P356
P1476
The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
@en
P2093
Andrew McMichael
Tomâs Hanke
P2860
P304
P356
10.1038/NRI779
P577
2002-04-01T00:00:00Z